What it is
Pancragen (KEDW; Lys-Glu-Asp-Trp) is a short peptide bioregulator associated with pancreatic function, insulin and C-peptide dynamics, glucose metabolism, and age-related metabolic research.
Mechanism of action
Pancragen is studied for tissue-specific regulation of pancreatic cell function and differentiation during aging, including endocrine pancreatic markers and glucose-metabolism support.
Evidence summary
Evidence includes old-monkey endocrine-function work, elderly type 2 diabetes reports, and peptide bioregulator differentiation studies. Treat as educational research support rather than a replacement for diabetes care.
Typical dosing protocols
- 20 mg vial reconstituted with 2.0 ml bacteriostatic water
- 500 mcg-1 mg subcutaneous daily
- 10-20 day courses; morning before food is most common
Side effects & safety
- Injection-site redness, tenderness, itching, or mild swelling
- Headache, nausea, lightheadedness, or digestive changes
- Customers using glucose-lowering medications should consult a clinician before use
Cited studies
- Goncharova ND, et al. (2015). Impact of tetrapeptide Pancragen on endocrine function of the pancreas in old monkeys. PubMed.PMID 25946840Read source โ
- Korkushko OV, et al. (2010). Efficacy of Pancragen peptide in elderly patients with type 2 diabetes mellitus. Problems of Endocrine Pathology.Read source โ
- Khavinson V, et al. (2012). Peptides tissue-specifically stimulate cell differentiation during aging. PubMed.PMID 22808515Read source โ
- Khavinson V, et al. (2013). Effects of Pancragen on differentiation of pancreatic cells during ageing. PubMed.PMID 23486591Read source โ
All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.